CombinatoRx, Incorporated Fights the Pain of BioTech Industry, Posts Great Results
World Market Media -- CombinatoRx reported their fourth quarter and year end results this morning at 8:30am. The pain and inflammation company is very excited about its approval of Exalgo (an extended release tablet for severe pain in opiod tolerant patients), as well as its full integration with Neuromed.